1. 大河内信弘,福永潔,野口雅之,他. (2013) 多発性肝嚢胞診療ガイドライン. 厚生労働省, 13-28．
2. Cnossen WR, Drenth JP. (2014) Polycystic liver disease: an overview of patho- genesis, clinical manifestations and management. Orphanet J Rare Dis, 9, 1- 13.
3. Khan S, Dennison A, Garcea G. (2016) Medical therapy for polycystic liver dis- ease. Ann R Coll Surg Engl, 98, 18-23.
4. 丸山彰一, 成田一衛, 岡田浩一, 他. (2017) エビデンスに基づく多発性嚢胞腎（PKD）診療ガイドライン 2017, 東京医学社, 26-58.
5. Nichols MT, Gidey E, Matzakos T, et al. (2004) Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology, 40, 836-46.
6. Temmerman F, Missiaen L, Bammens B, et al. (2011) Systematic review: the pathophysiology and management of polycystic liver disease. Aliment Pharma- col Ther, 34, 702-13.
7. Perugorria MJ, Masyuk TV, Marin JJ, et al. (2014) Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol, 11, 750-61.
8. Strazzabosco M, Somlo S. (2011) Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology, 140, 1855-9.
9. Takiar V, Nishio S, Seo-Mayer P, et al. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A, 108, 2462- 7.
10. Meliana R, Sarika K, Daniel R, et al. (2016) Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease. PLoS One, 11, 1- 17.
11. Hogan MC, Masyuk TV, Page LJ, et al. (2010) Randomized clinical trial of long- acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol, 21, 1052-61.
12. Hogan MC, Masyuk T, Bergstralh E, et al. (2015) Efficacy of 4 years of oc- treotide long-acting release therapy in patients with severe polycystic liver dis- ease. Mayo Clin Proc, 90, 1030-7.
13. Mizuno H, Hoshino J, Suwabe T, et al. (2017) Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease. Case Rep Nephrol Dial, 7, 108-111.
14. Torres VE, Chapman AB, Devuyst O, et al. (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med, 367, 2407-18.
15. Zhou G, Myers R, Li Y, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74.
16. Foretz M, Guigas B, Bertrand L, et al. (2014) Metformin: from mechanisms of action to therapies. Cell Metab, 20, 953-66.
17. Oh S, So R, Shida T. et al. (2017) High-Intensity Aerobic Exercise Improves Both Hepatic Fat Content and Stiffness in Sedentary Obese Men with Nonal- coholic Fatty Liver Disease. Sci Rep, 22, 1-12.
18. Zenith L, Meena N, Ramadi A, et al. (2014) Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol, 12, 1920-1926.
19. Debette-Gratien M, Tabouret T, Antonini MT, et al. (2015) Personalized adapted physical activity before liver transplantation: acceptability and results. Transplantation, 99, 145-150.
20. Behrens G, Matthews CE, Moore SC, et al. (2013) The association between fre- quency of vigorous physical activity and hepatobiliary cancers in the NIH- AARP Diet and Health Study. Eur J Epidemiol, 28, 55-66.
21. Linden MA, Sheldon RD, Meers GM, et al. (2016) Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis. J Physiol, 594, 5271-84.
22. Mikami T, Sumida S, Ishibashi Y, et al. (2004) Endurance exercise training in- hibits activity of plasma GOT and liver caspase-3 of mice [correction of rats] exposed to stress by induction of heat shock protein 70. J Appl Physiol, 96, 1776- 1781.
23. Piguet AC, Saran U, Simillion C, et al. (2015) Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. J Hepatol, 62, 1296-303.
24. Shimomura Y, Brock WJ, Ito Y, et al. (2015) Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease. Int J Toxicol, 34, 479-90.
25. Masyuk TV, Huang BQ, Masyuk AI, et al. (2004) Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney dis- ease. Am J Pathol, 165, 1719-30.
26. Ren XS, Sato Y, Harada K, et al. (2014) Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS One, 9, 1-14.
27. Munoz-Garrido P, Marin JJ, Perugorria MJ, et al. (2015) Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol, 63, 952-61.
28. Yoshihara D, Kugita M, Sasaki M, et al. (2013) Telmisartan ameliorates fibro- cystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. PLoS One, 8, 1-8.
29. Yoshihara D, Kurahashi H, Morita M, et al. (2011) PPAR-gamma agonist ame- liorates kidney and liver disease in an orthologous rat model of human autoso- mal recessive polycystic kidney disease. Am J Physiol Renal Physiol, 300, 465- 74.
30. Carlson CL, Winder WW. (1999) Liver AMP-activated protein kinase and ace- tyl-CoA carboxylase during and after exercise. J Appl Physiol, 86, 669-74.
31. Linden MA, Fletcher JA, Morris EM, et al. (2014) Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. Am J Physiol Endocrinol Metab, 306, 300-10.
32. 佐藤陽一, 三浦平寛, 仇嘉禾, 他. (2017) 多発性肝嚢胞モデルラットの肝病変に対する長期的運動の効果. 運動器リハビリテーション, 28, 421-427.
33. Ito D, Cao P, Kakihana T. et al. (2015) Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. PLoS One, 10, 1-21.
34. Bradford MM. (1976) A rapid and sensitive method for the quantitation of mi- crogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
35. Chandok N. (2012) Polycystic liver disease: a clinical review. Ann Hepatol, 11, 819-26.
36. Khan S, Dennison A, Garcea G. (2016) Medical therapy for polycystic liver dis- ease. Ann R Coll Surg Engl, 98, 18-23.
37. Grantham JJ. (2015) Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol, 30, 1053-62.
38. Darnley MJ, DiMarco NM, Aukema HM. (2000) Safety of chronic exercise in a rat model of kidney disease. Med Sci Sports Exerc, 32, 576-80.
39. Jiralerspong S, Palla SL, Giordano SH, et al. (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27, 3297-302.
40. Gonzalez-Angulo AM, Meric-Bernstam F. (2010) Metformin: a therapeutic op- portunity in breast cancer. Clin Cancer Res, 16, 1695-700.
41. Pisani A, Riccio E, Bruzzese D, et al. (2018) Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?. BMC Neph- rol, 19, 1-5.
42. Seliger SL, Abebe KZ, Hallows KR, et al. (2018) A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol, 47, 352-60.
43. Takekoshi K, Fukuhara M, Quin Z, et al. (2006) Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit ex- pression in rat visceral adipose tissue and liver. Metabolism, 55, 1122-8.
44. Nakanuma Y, Harada K, Sato Y, et al. (2010) Recent progress in the etiopatho- genesis of pediatric biliary disease, particularly Caroli's disease with congenital hepatic fibrosis and biliary atresia. Histol Histopathol, 25, 223-35.
45. Temmerman F, Chen F, Libbrecht L, et al. (2017) Everolimus halts hepatic cys- togenesis in a rodent model of polycystic-liver-disease. World J Gastroenterol, 23, 5499-507.
46. Souza Pauli LS, Ropelle EC, de Souza CT, et al. (2014) Exercise training de- creases mitogen-activated protein kinase phosphatase-3 expression and sup- presses hepatic gluconeogenesis in obese mice. J Physiol, 592, 1325-40.
47. Gao Y, Zhang W, Zeng LQ, et al. (2020) Exercise and dietary intervention ame- liorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy. Re- dox Biol, 36, 1-14.
48. Banales JM, Masyuk TV, Bogert PS, et al. (2008) Hepatic cystogenesis is asso- ciated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol, 173, 1637-46.
49. Li D, Shi X, Zhao L, et al. (2016) Overexpression of Aquaporin 1 on cysts of patients with polycystic liver disease. Rev Esp Enferm Dig, 108, 71-8.
50. Lee SO, Masyuk T, Splinter P, et al. (2008) MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest, 118, 3714-24.
51. Yamaguchi T, Nagao S, Darren PW, et al. (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int, 63, 1983-94.
52. Yu Q, Kou W, Xu X, et al. (2019) FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clin Sci (Lond), 133, 611-27.
53. Roehlen N, Crouchet E, Baumert TF. (2020) Liver Fibrosis: Mechanistic Con- cepts and Therapeutic Perspectives. Cells, 9, 1-43.
54. Sato Y, Harada K, Ozaki S, et al. (2007) Cholangiocytes with mesenchymal fea- tures contribute to progressive hepatic fibrosis of the polycystic kidney rat. Am J Pathol, 171, 1859-71.
55. 佐藤 保則. (2013) Caroli 病と先天性肝線維症の病態解析 : 動物モデル PCK ラットから得られた新たな知見. 金沢大学十全医学会雑誌, 122, 24-8.
56. Kawanishi N, Yano H, Mizokami T, et al. (2012) Exercise training attenuates hepatic inflammation, fibrosis and macrophage infiltration during diet induced- obesity in mice. Brain Behav Immun, 26, 931-41.
57. Tripathi DM, Erice E, Lafoz E, et al. (2015) Metformin reduces hepatic re- sistance and portal pressure in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol, 309, 301-9.
58. Zacarias AC, Barbosa MA, Guerra-Sá R, et al. (2017) Swimming training in- duces liver adaptations to oxidative stress and insulin sensitivity in rats sub- mitted to high-fat diet. Redox Rep, 22, 515-23.
59. Lemyze M, Dharancy S, Wallaert B. (2013) Response to exercise in patients with liver cirrhosis: implications for liver transplantation. Dig Liver Dis, 45, 362-6.
60. Carey EJ, Steidley DE, Aqel BA, et al. (2010) Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl, 16, 1373-8.
61. Tandon P, Ismond KP, Riess K, et al. (2018) Exercise in cirrhosis: Translating evidence and experience to practice. J Hepatol, 69, 1164-77.
62. Reinecke NL, Cunha TM, Heilberg IP, et al. (2014) Exercise capacity in poly- cystic kidney disease. Am J Kidney Dis, 64, 239-46.
63. Temmerman F, Ho TA, Vanslembrouck R, et al. (2015) Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Pa- tients With Symptomatic Polycystic Liver Disease. Clin Gastroenterol Hepatol, 13, 2353-9.
64. 上月正博, 伊藤修, 小川美歌, 他. (2009) 内部障害のリハビリテーション, 医歯薬出版株式会社, 東京, 32-3.
65. Hu G, Xu L, Ma Y, et al. (2020) Chronic exercise provides renal-protective ef- fects with upregulation of fatty acid oxidation in the kidney of high fructose-fed rats. Am J Physiol Renal Physiol, 318, 826-34.
論文の公開元へ
